Adherence to antipsychotic medication: discontinued medication · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adherence to antipsychotic medication: discontinued medication compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · people with both severe mental illness and substance misuse
1 finding from 1 review
Substance use: 1. Reduction of cannabis use‐change data (number of joints smoked/week) · people with both severe mental illness and substance misuse
1 finding from 1 review
Quality of life: substantial improvement · schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · schizophrenia
QUETIAPINE probably leads to lower adverse effects: 1. Sedation compared with CLOZAPINE ‐ all data short term (moderate certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
1 finding from 1 review
Weight gain · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain compared with CLOZAPINE ‐ all data short term (low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia
1 finding from 1 review
Weight gain · people with psychosis
1 finding from 1 review
No improvement (clozapine vs olanzapine) · people with psychosis
1 finding from 1 review
Use of other antipsychotics · people with psychosis
1 finding from 1 review
Drug‐induced diabetes (clozapine vs olanzapine) · people with psychosis
1 finding from 1 review
Elevated prolactin (risperidone vs quetiapine) · people with psychosis
1 finding from 1 review
Weight gain · people with psychosis
1 finding from 1 review
Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis
1 finding from 1 review
No response · people with psychosis
1 finding from 1 review
Symptomatic hyperprolactinaemia · people with psychosis
1 finding from 1 review
Use of antiparkinsonian medications · people with psychosis
1 finding from 1 review